The Latest Cardiac and Vascular News
Accepted abstracts include a Late Breaker presentation of the OMNY-AF Pilot and real-world safety and efficiency data for the VARIPULSE Platform Introduction of the VARIPULSE Plus Platform reinforces Johnson & Johnson’s commitment to continued innovation Irvine, CA – February 3, 2026 – Johnson & Johnson is announcing new portfolio innovations in […]
SANTA CLARA, Calif. – September 15, 2025 – Today, Johnson & Johnson announced the European launch of its Shockwave Javelin Peripheral IVL Catheter, a novel intravascular lithotripsy (IVL) platform designed to modify calcium in extremely narrowed vessels to expand treatments in patients suffering from peripheral artery disease (PAD). The first-of-its-kind Forward IVL […]
Now available in the U.S., the Shockwave Javelin Peripheral Intravascular Lithotripsy Catheter safely modifies and crosses occlusive or extremely narrowed calcific peripheral artery disease SANTA CLARA, Calif., March 4, 2025 /PRNewswire/ — Today, Shockwave Medical, Inc., part of Johnson…
CINCINNATI, Dec. 13, 2024 /PRNewswire/ — In a groundbreaking achievement for pediatric heart care, the FDA has expanded the labeling of Johnson & Johnson MedTech’s Impella Support System to include treatment for certain children suffering from heart failure, extending the original…
The VARIPULSE™ Platform is the first and only Pulsed Field Ablation (PFA) System in the U.S. fully integrated with the CARTO™ 3 Electro-anatomical Mapping System, driving efficiency, reproducibility and accuracy1 Approval is supported by the admIRE study, where 85% peak primary…
The OMNY-AF trial evaluates safety and efficacy of the investigational OMNYPULSE™ Platform, a novel catheter that combines a large ablation area with mapping capabilities Irvine, CA – October 30, 2024 – Today, Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, announced the enrollment completion of the […]
2024 Second-Quarter reported sales growth of 4.3% to $22.4 Billion with operational growth of 6.6%* and adjusted operational growth of 6.5%*. Adjusted operational growth excluding COVID-19 Vaccine of 7.1%* 2024 Second-Quarter Earnings per share (EPS) of $1.93 decreasing by 5.9% due to one-time special charges and adjusted EPS of $2.82 […]
NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech. “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory […]
April 05, 2024 06:31 AM Eastern Daylight Time NEW BRUNSWICK, N.J. & SANTA CLARA, Calif.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 […]
On behalf of Johnson & Johnson, we have exciting organizational news to share, which will continue to help advance our mission to enable a healthier future for patients. Celine Martin has recently been appointed to the new role of Company Group Chairman, Cardiovascular & Specialty Solutions (CSS) Group. In this […]
